10 results

• Eliquis, Xarelto Bleeding Risks Renewed Amid Andexxa Recall Tied to Stroke, Heart Attack Concerns

  January 9, 2026

  Irvin Jackson

  Recent recall of Andexxa causes Xarelto and Eliquis users to go without an FDA-approved reversal agent, leaving doctors to rely on a drug known to be less effective and to cause blood clots.

• Andexxa Recall Announced After FDA Says Xarelto, Eliquis Reversal Agent Risks Outweigh Benefits

  December 22, 2025

  Irvin Jackson

  AstraZeneca is removing its blood thinner reversal agent Andexxa from the market after the FDA determined the drug's blood clot risks outweigh its benefits.

• Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis

  November 21, 2024

  Irvin Jackson

  Safety concerns linked to Andexxa, the reversal agent for newer blood thinners like Xarelto and Eliquis, will be discussed at an FDA advisory panel meeting today, after postmarketing studies indicated the drug doubled the risks of blood clots and death.

• Fatal Bleeding Still Occurring With New Blood Thinners Despite Antidotes: Study

  June 21, 2021

  Irvin Jackson

  A new study reveals that death rates from bleeding events linked to new blood thinners like Pradaxa and Xarelto are still high, despite the introduction of reversal agents meant to counteract the drugs' blood thinning effects.

• Andexxa Helped 82% Of Xarelto and Eliquis Patients Suffering Bleeding Problems: Study

  February 19, 2019

  Irvin Jackson

  A new study indicates that the Xarelto and Eliquis reversal agent Andexxa restores 82% of patients to excellent or good hemostasis following a major bleeding event caused by the blood thinners.

• Antidote For Xarelto, Eliquis Bleeding Events Approved For Large-Scale Production

  January 8, 2019

  Irvin Jackson

  The FDA has approved Andexxa, a reversal agent for Xarelto and Eliquis, for large-scale production in the face of growing bleeding injury reports.

• Xarelto Antidote Andexxa To Only Get Limited Release To 40-50 Hospitals, Investors Told

  May 10, 2018

  Irvin Jackson

  The release of the highly anticipated Xarelto reversal agent, AndexXa, will be limited to only 40 to 50 hospitals until at least next year, due to concerns the FDA has over the manufacturing process, Portolo Pharmaceuticals CEO told investors.

• FDA Approves AndexXa as Reversal Agent For Xarelto, Eliquis

  May 7, 2018

  Irvin Jackson

  A new reversal agent has been approved for Xarelto and Eliquis but will only continue to be approved if postmarketing studies find no problems.

• Xarelto Reversal Agent Delayed Again, More Clinical Trials May Be Needed

  March 7, 2018

  Irvin Jackson

  The FDA is calling for clinical trials before it will approve the long-delayed Xarelto and Eliquis reversal agent, AndexXa.

• Proposed Xarelto, Eliquis Reversal Agent Raises Questions Among Some Doctors

  December 22, 2016

  Irvin Jackson

  Some doctors are expressing concerns about the safety and efficacy of a proposed reversal agent for the blood thinners Eliquis and Xarelto.